



**Final Appraisal Recommendation**

Advice No: 0714 – February 2014

**Tenofovir disoproxil (as fumarate) (Viread®)  
245 mg film-coated tablets and 33 mg/g granules**

**Limited submission by Gilead Sciences Ltd**

**Recommendation of AWMSG**

**Tenofovir disoproxil (as fumarate) (Viread®) 245 mg film-coated tablets are recommended as an option for use within NHS Wales for the treatment of chronic hepatitis B in adults with evidence of lamivudine-resistant hepatitis B virus.**

**Tenofovir disoproxil (as fumarate) (Viread®) 33 mg/g granules are recommended as an option for use within NHS Wales for the treatment of chronic hepatitis B in adults for whom a solid dosage form is not appropriate with evidence of lamivudine-resistant hepatitis B virus.**

**Additional note:**

- Please refer to the Summary of Product Characteristics for the full licensed indication.

In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2006), which includes the AWMSG Secretariat Assessment Report (ASAR), the Preliminary Appraisal Recommendation (PAR) and the applicant company's response to the PAR, clinical expert opinion (where available), the views of patients/patient carers (where available) and the lay member perspective.

This recommendation has been ratified by Welsh Government and will be considered for review every three years.

Marketing authorisation holder on first issue:	Gilead Sciences Ltd
Date of first issue	February 2014
Last reviewed	May 2017



NICE has accredited the process used by the All Wales Medicines Strategy Group (AWMSG) to produce its final appraisal recommendation. Accreditation is valid for 5 years from October 2011. More information on accreditation can be viewed at [www.evidence.nhs.uk](http://www.evidence.nhs.uk).

For full details on our accreditation visit: [www.nice.org.uk/accreditation](http://www.nice.org.uk/accreditation).

Statement of use: No part of this recommendation may be reproduced without the whole recommendation being quoted in full and cited as:

All Wales Medicines Strategy Group. Final Appraisal Recommendation – 0714:  
Tenofovir disoproxil (as fumarate) (Viread<sup>®</sup>) 245 mg film-coated tablets and 33 mg/g granules.  
February 2014.

